UK – NICE recommendation for Steglatro in type II diabetes

The National Institute of Care and Health Excellence (NICE) has recommended MSD’s Steglatro (ertugliflozin) for use within the NHS, for the treatment of adults with type II diabetes.

The recommendation for the sodium-glucose cotransporter-2 (SGLT-2) inhibitor is as monotherapy in adults with type II diabetes that cannot tolerate metformin, or as part of a dual therapy regimen in combination with metformin.

The treatment offers a new option for people with the disorder with a 20% lower acquisition cost than other SGLT-2 inhibitors, with the price of a once daily dose costing just £29.40 for 28 days’ treatment.

The decision is based on results from the VERTIS-MONO, VERTIS-MET and VERTIS-FACTORIAL trials, in which the drug showed significant change in HbA1c from baseline to week 26…